However, a more recently developed selective and reversible FASN inhibitor (TVB-2640) has shown promising results, including dose-dependent efficacy in advanced solid tumors like HER2-positive breast cancers and has advanced to Phase II clinical trials [17]. The gene discussed is ERBB2; the disease is breast carcinoma.